

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM752454

SUBMISSION TYPE:	RESUBMISSION		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
RESUBMIT DOCUMENT ID:	900708592		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
ENDOCYTE, INC.		12/15/2021	Company: DELAWARE
RECEIVING PARTY DATA			
Name:	Novartis AG		
Street Address:	CH-4002		
City:	Basel		
State/Country:	SWITZERLAND		
Postal Code:	4002		
Entity Type:	Aktiengesellschaft (Ag): SWITZERLAND		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Registration Number:	4740077		
Registration Number:	4813625	ENDOCYTE	
Serial Number:	88758613	PLUVICTO	
CORRESPONDENCE DATA			
Fax Number:	9198618913		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	9198618903		
Email:	mtepper@teiplaw.com		
Correspondent Name:	Maury M. Tepper		
Address Line 1:	3724 BENSON DR		
Address Line 4:	RALEIGH, NORTH CAROLINA 27609		
ATTORNEY DOCKET NUMBER:	ENDOCYTE ASSIGNMENT		
DOMESTIC REPRESENTATIVE			
Name:	Novartis Pharmaceuticals Corporation		
Address Line 1:	One Health Plaza, Building 430		
Address Line 4:	East Hanover, NEW JERSEY 07936		
NAME OF SUBMITTER:	Maury M. Tepper, III		

SIGNATURE:	/Maury M. Tepper, III/
DATE SIGNED:	08/31/2022
Total Attachments: 7 source=Notice (003)#page1.tif source=TM Assignment Agreement#page1.tif source=TM Assignment Agreement#page2.tif source=TM Assignment Agreement#page3.tif source=TM Assignment Agreement#page4.tif source=TM Assignment Agreement#page5.tif source=TM Assignment Agreement#page6.tif	

TRADEMARK ASSIGNMENT AGREEMENT

This TRADEMARK ASSIGNMENT AGREEMENT (the "Assignment") dated as of December 15, 2021 (the "Effective Date"), is entered into by and between Endocyte, Inc., a company organized under the laws of the United States of America and located at 3000 Kent Avenue, West Lafayette, IN 47906 ("Assignor") and Novartis AG, a company organized under the laws of Switzerland ("Assignee"), located at 4002 Basel Switzerland. The Assignors and Assignee are referred to herein individually as "Party" or collectively as "Parties."

PRELIMINARY STATEMENTS

WHEREAS, Assignor desires to assign to Assignee, and Assignee desires to receive, the trademarks, trade names, and trademark applications set forth on Schedule A hereto (the "Transferred Trademarks") and all goodwill associated therewith or symbolized thereby.

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements contained in this Assignment, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged:

1. Assignment. Assignor hereby assigns and transfers to Assignee, its successors and assigns, and Assignee hereby accepts, all of Assignor's right, title and interest in and to the following: (a) the Transferred Trademarks, including without limitation any renewals thereof, together with all of the goodwill of the business symbolized by or associated therewith, and together with (i) all common law rights thereto; (ii) the right to prosecute, maintain and defend the Transferred Trademarks before any public or private agency, office or registrar; and (iii) the right, if any, to claim priority based on the filing dates of any of the Transferred Trademarks under the Paris Convention, and all other treaties of like purposes; and (b) all rights to causes of action (whether known or unknown or whether currently pending, filed or otherwise) under, or on account of, any of the Transferred Trademarks, including the right to sue for past, current and future infringement, dilution or other violation of the Transferred Trademarks and obtain in connection therewith (i) damages; (ii) injunctive relief; and (iii) any other remedies of any kind; with all of the foregoing rights to be held and enjoyed by Assignee for its own use and enjoyment and the use and enjoyment of its successors, assigns and other legal representatives to the end of the term or terms for which the Transferred Trademarks are granted, reissued, renewed, extended or revived as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment had not been made.


2. Cooperation. Assignor agrees, at the request and expense of Assignee, to take or cause to be taken all such other actions, including without limitation the execution of any and all other instruments in writing, including affidavits, powers of attorney, assignments and other documents, which may be reasonably required or necessary to more effectively perfect in, secure to, record in the name of, protect and vest in, Assignee and its successors and assigns, the entire right, title and interest in and to the Transferred Trademarks.


3. Recordation. Assignee shall be responsible for all costs, including all filing costs and external fees, associated with recordation and/or registration of this Assignment or any other document evidencing the assignment from each Assignor to Assignee of the Transferred Trademarks. Assignor hereby authorizes the relevant authorities, entities or agencies in any applicable foreign countries or multinational authorities to record Assignee as the purchaser and owner of the Transferred Trademarks and to deliver to Assignee, and to Assignee's attorneys, agents, successors or assigns, all official documents and communications as may be warranted by this Assignment.

IN WITNESS WHEREOF, The Assignors and Assignee have caused this Assignment to be executed on the date first written above by their respective duly authorized officers.

ASSIGNOR


By: Endocyte, Inc.


Signature: 
Name: _____
Title: **Wojciech Kraft**
Authorized Signatory

Signature: 
Name: _____
Title: **Ian James Hiscock**
Authorized Signatory

ASSIGNEE

By: Novartis AG

Signature: 
Name: _____
Title: **Markus Gruber**

Signature: 
Name: _____
Title: **Maria Bolognani**
Authorized Signatory

CASEREFFERENCE	MARK	CLASSES	COUNTRY	FILING-TYPE	PROSECUTION STEP	FILING DATE	REG. DATE	REG. NUMBER	REG. OWNERS
TMA040038-AU-MP	ENDOCYTE	05, 42	Australia	MP	Registered	2011.10.21	2011.10.21	1097674	Endocyte, Inc.
TMA040038-BR-NF	ENDOCYTE	42	Brazil	NF	Registered	2011.10.28	2015.05.05	904202364	Endocyte, Inc.
TMA040038-CA-NF	ENDOCYTE	05, 42	Canada	NF	Registered	2011.10.25	2015.02.23	TMA897205	Endocyte, Inc.
TMA040038-CN-MP	ENDOCYTE	05, 42	China	MP	Registered	2011.10.21	2011.10.21	1097674	Endocyte, Inc.
TMA040038-CO-MP	ENDOCYTE	05, 42	Colombia European Union	MP	Registered	2014.04.28	2014.04.28	1097674	Endocyte, Inc.
TMA040038-EM-CM	ENDOCYTE	05, 42	European Union	CM	Registered	2011.10.25	2012.03.28	10368512	Endocyte, Inc.
TMA040038-IN-NF	ENDOCYTE	05, 42	India	NF	Registered	2011.10.25	2011.10.25	2225695	Endocyte, Inc.
TMA040038-ID-NF	ENDOCYTE	05, 42	Indonesia	NF	Registered	2011.11.25	2014.03.12	IDM000408976	Endocyte, Inc.
TMA040038-WO-MA	ENDOCYTE	05, 42	International Procedure	MA	Registered	2011.10.21	2011.10.21	1097674	Endocyte, Inc.
TMA040038-WO-MA02	ENDOCYTE	05, 42	International Procedure	MA	Registered	2011.10.29	2011.10.29	1097498	Endocyte, Inc.
TMA040038-IL-MP	ENDOCYTE	05, 42	Israel	MP	Registered	2011.10.21	2011.10.21	1097674	Endocyte, Inc.
TMA040038-JP-NF	ENDOCYTE	05, 42	Japan	NF	Registered	2011.10.26	2012.08.31	5518318	Endocyte, Inc.
TMA040038-NZ-NF	ENDOCYTE	05, 42	New Zealand	NF	Registered	2011.10.25	2013.03.22	851370	Endocyte, Inc.
TMA040038-NZ-NF02	ENDOCYTE	05, 42	New Zealand	NF	Registered	2012.10.09	2013.04.10	966783	Endocyte, Inc.
TMA040038-NO-MP	ENDOCYTE	05, 42	Norway	MP	Registered	2014.04.28	2014.04.28	1097674	Endocyte, Inc.
TMA040038-SG-MP	ENDOCYTE	05, 42	Singapore	MP	Registered	2014.04.28	2014.04.28	1097674	Endocyte, Inc.
TMA040038-ZA-NF02	ENDOCYTE	42	South Africa	NF	Registered	2011.10.26	2013.07.31	2011/27067	Endocyte, Inc.
TMA040038-ZA-NF	ENDOCYTE	5	South Africa	NF	Registered	2011.10.26	2013.07.31	2011/27066	Endocyte, Inc.
TMA040038-KR-MP	ENDOCYTE	05, 42	South Korea / Republic of Korea	MP	Registered	2011.10.21	2011.10.21	1097674	Endocyte, Inc.
TMA040038-TW-NF	ENDOCYTE	05, 42	Taiwan	NF	Registered	2011.10.28	2012.09.01	1535500	Endocyte, Inc.
TMA040038-TR-MP02	ENDOCYTE	05, 42	Turkey	MP	Registered	2011.10.29	2011.10.29	1097498	Endocyte, Inc.
TMA040038-TR-MP	ENDOCYTE	05, 42	Turkey	MP	Registered	2014.04.28	2014.04.28	1097674	Endocyte, Inc.
TMA040038-GB-NF	ENDOCYTE	05, 42	United Kingdom	NF	Registered	2011.10.25	2012.03.28	UK00910368512	Endocyte, Inc.
TMA040038-VN-MP	ENDOCYTE	05, 42	Vietnam	MP	Registered	2014.04.28	2014.04.28	1097674	Endocyte, Inc.
TMA040043-US-NF	ENDOCYTE & Design (2014)	42	United States of America	NF	Registered	2013.12.26	2015.09.15	4813625	Endocyte, Inc.
TMA040044-AU-MP	Endocyte Logo (2014)	05, 42	Australia	MP	Registered	2014.04.28	2014.04.28	1210503	Endocyte, Inc.
TMA040044-CN-MP	Endocyte Logo (2014)	05, 42	China	MP	Registered	2014.04.28	2014.04.28	1210503	Endocyte, Inc.

TMA040044-CO-MP	Endocyte Logo (2014)	05, 42	Colombia	MP	Registered	2014.04.28	2014.04.28	1210503	Endocyte, Inc.
TMA040044-EM-MP	Endocyte Logo (2014)	05, 42	European Union	MP	Registered	2014.04.28	2014.04.28	1210503	Endocyte, Inc.
TMA040044-IN-MP	Endocyte Logo (2014)	05, 42	India	MP	Registered	2014.04.28	2014.04.28	1210503	Endocyte, Inc.
TMA040044-WO-MA	Endocyte Logo (2014)	05, 42	International Procedure	MA	Registered	2014.04.28	2014.04.28	1210503	Endocyte, Inc.
TMA040044-IL-MP	Endocyte Logo (2014)	05, 42	Israel	MP	Registered	2014.04.28	2014.04.28	1210503	Endocyte, Inc.
TMA040044-JP-MP	Endocyte Logo (2014)	05, 42	Japan	MP	Registered	2014.04.28	2014.04.28	1210503	Endocyte, Inc.
TMA040044-MX-MP	Endocyte Logo (2014)	05, 42	Mexico	MP	Registered	2014.04.28	2014.04.28	1210503	Endocyte, Inc.
TMA040044-NO-MP	Endocyte Logo (2014)	05, 42	Norway	MP	Registered	2014.04.28	2014.04.28	1210503	Endocyte, Inc.
TMA040044-RU-MP	Endocyte Logo (2014)	05, 42	Russian Federation	MP	Registered	2014.04.28	2014.04.28	1210503	Endocyte, Inc.
TMA040044-SG-MP	Endocyte Logo (2014)	05, 42	Singapore	MP	Registered	2014.04.28	2014.04.28	1210503	Endocyte, Inc.
TMA040044-KR-MP	Endocyte Logo (2014)	05, 42	South Korea / Republic of Korea	MP	Registered	2014.04.28	2014.04.28	1210503	Endocyte, Inc.
TMA040044-CH-MP	Endocyte Logo (2014)	05, 42	Switzerland	MP	Registered	2014.04.28	2014.04.28	1210503	Endocyte, Inc.
TMA040044-TR-MP	Endocyte Logo (2014)	05, 42	Turkey	MP	Registered	2014.04.28	2014.04.28	1210503	Endocyte, Inc.
TMA040044-GB-NF	Endocyte Logo (2014)	05, 42	United Kingdom	NF	Registered	2014.04.28	2014.04.28	UK00801210503	Endocyte, Inc.
TMA040044-US-NF	Endocyte Logo (2014)	05, 42	United States of America	NF	Registered	2013.12.26	2015.05.19	4740077	Endocyte, Inc.
TMA040044-VN-MP	Endocyte Logo (2014)	05, 42	Vietnam	MP	Registered	2014.04.28	2014.04.28	1210503	Endocyte, Inc.
TMA040119-EM-CM	LUPLUSMEA	5	European Union	CM	Registered	2020.01.16	2020.06.06	18181202	Endocyte, Inc.
TMA040119-IS-NF	LUPLUSMEA	5	Iceland	NF	Registered	2020.01.17	2020.02.29	V0115967	Endocyte, Inc.
TMA040119-JP-NF	LUPLUSMEA	5	Japan	NF	Registered	2020.01.20	2021.01.28	6346164	Endocyte, Inc.
TMA040119-NO-NF	LUPLUSMEA	5	Norway	NF	Registered	2020.01.16	2020.08.04	310886	Endocyte, Inc.
TMA040119-CH-NF	LUPLUSMEA	5	Switzerland	NF	Registered	2020.02.06	2020.06.16	748401	Endocyte, Inc.
TMA040119-TR-NF	LUPLUSMEA	5	Turkey	NF	Registered	2020.01.16	2020.10.04	2020/06051	Endocyte, Inc.
TMA040119-GB-NF	LUPLUSMEA	5	United Kingdom	NF	Registered	2020.01.16	2020.08.07	UK00003458626	Endocyte, Inc.
TMA040119-GB-NF02	LUPLUSMEA	5	United Kingdom	NF	Registered	2020.01.16	2020.06.06	UK00918181202	Endocyte, Inc.

TMA040119-US-NF	LUPLUSMEA	5	United States of America	NF	Pending	2020.01.14			Endocyte, Inc.
TMA040120-EM-CM	LUPLUSMIA	5	European Union	CM	Registered	2020.01.16	2020.06.06	18181217	Endocyte, Inc.
TMA040120-IS-NF	LUPLUSMIA	5	Iceland	NF	Registered	2020.01.17	2020.02.29	V0115968	Endocyte, Inc.
TMA040120-JP-NF	LUPLUSMIA	5	Japan	NF	Registered	2020.01.20	2021.02.12	6351421	Endocyte, Inc.
TMA040120-NO-NF	LUPLUSMIA	5	Norway	NF	Registered	2020.01.16	2020.08.04	310887	Endocyte, Inc.
TMA040120-CH-NF	LUPLUSMIA	5	Switzerland	NF	Registered	2020.02.06	2020.06.16	748405	Endocyte, Inc.
TMA040120-TR-NF	LUPLUSMIA	5	Turkey	NF	Registered	2020.01.16	2020.08.13	2020/06053	Endocyte, Inc.
TMA040120-GB-NF02	LUPLUSMIA	5	United Kingdom	NF	Registered	2020.01.16	2020.06.06	UK00918181217	Endocyte, Inc.
TMA040120-GB-NF	LUPLUSMIA	5	United Kingdom	NF	Registered	2020.01.16	2020.08.07	UK00003458631	Endocyte, Inc.
TMA040120-US-NF	LUPLUSMIA	5	United States of America	NF	Pending	2020.01.14			Endocyte, Inc.
TMA040122-EM-CM	PLUVICTO	5	European Union	CM	Registered	2020.01.16	2020.12.18	18181192	Endocyte, Inc.
TMA040122-IS-NF	PLUVICTO	5	Iceland	NF	Registered	2020.01.17	2020.02.29	V0115969	Endocyte, Inc.
TMA040122-JP-NF	PLUVICTO	5	Japan	NF	Registered	2020.01.20	2021.01.28	6346165	Endocyte, Inc.
TMA040122-NO-NF	PLUVICTO	5	Norway	NF	Registered	2020.01.16	2020.08.04	310888	Endocyte, Inc.
TMA040122-CH-NF	PLUVICTO	5	Switzerland	NF	Registered	2020.02.06	2020.06.16	748404	Endocyte, Inc.
TMA040122-TR-NF	PLUVICTO	5	Turkey	NF	Registered	2020.01.16	2020.08.11	2020/06056	Endocyte, Inc.
TMA040122-GB-NF02	PLUVICTO	5	United Kingdom	NF	Registered	2020.01.16	2020.12.18	UK00918181192	Endocyte, Inc.
TMA040122-GB-NF	PLUVICTO	5	United Kingdom	NF	Registered	2020.01.16	2020.12.25	UK00003458696	Endocyte, Inc.
TMA040122-US-NF	PLUVICTO	5	United States of America	NF	Pending	2020.01.14			Endocyte, Inc.
TMA040037-EM-CM	POSMADIGM	5	European Union	CM	Registered	2019.08.29	2020.01.30	18117603	Endocyte, Inc.
TMA040037-IS-NF	POSMADIGM	5	Iceland	NF	Registered	2020.01.13	2020.01.31	V0115954	Endocyte, Inc.
TMA040037-JP-NF	POSMADIGM	5	Japan	NF	Registered	2020.01.14	2020.12.08	6325933	Endocyte, Inc.
TMA040037-NO-NF	POSMADIGM	5	Norway	NF	Registered	2020.01.15	2020.04.04	310885	Endocyte, Inc.
TMA040037-CH-NF	POSMADIGM	5	Switzerland	NF	Registered	2020.02.06	2020.06.16	748406	Endocyte, Inc.
TMA040037-TR-NF	POSMADIGM	5	Turkey	NF	Pending	2020.01.13			Endocyte, Inc.
TMA040037-GB-NF	POSMADIGM	5	United Kingdom	NF	Registered	2020.01.13	2020.03.27	UK00003457416	Endocyte, Inc.
TMA040037-GB-NF02	POSMADIGM	5	United Kingdom	NF	Registered	2019.08.29	2020.01.30	UK00918117603	Endocyte, Inc.

TMA040037-US-NF	POSMADIGM	05PH	United States of America	NF	Pending	2019.08.28			Endocyte, Inc.
TMA040121-EM-CM	VIPLUSMA	5	European Union	CM	Registered	2020.01.16	2020.06.06	18181196	Endocyte, Inc.
TMA040121-IS-NF	VIPLUSMA	5	Iceland	NF	Registered	2020.01.17	2020.02.29	V0115970	Endocyte, Inc.
TMA040121-JP-NF	VIPLUSMA	5	Japan	NF	Registered	2020.01.20	2021.01.28	6346166	Endocyte, Inc.
TMA040121-NO-NF	VIPLUSMA	5	Norway	NF	Registered	2020.01.16	2020.08.04	310889	Endocyte, Inc.
TMA040121-CH-NF	VIPLUSMA	5	Switzerland	NF	Registered	2020.02.06	2020.06.16	748403	Endocyte, Inc.
TMA040121-TR-NF	VIPLUSMA	5	Turkey	NF	Registered	2020.01.16	2020.09.23	2020/06055	Endocyte, Inc.
TMA040121-GB-NF	VIPLUSMA	5	United Kingdom	NF	Registered	2020.01.16	2020.08.07	UK00003458697	Endocyte, Inc.
TMA040121-GB-NF02	VIPLUSMA	5	United Kingdom	NF	Registered	2020.01.16	2020.06.06	UK00918181196	Endocyte, Inc.
TMA040121-US-NF	VIPLUSMA	5	United States of America	NF	Pending	2020.01.14			Endocyte, Inc.